Some studies have shown that KDM3B has potential tumor-suppressive activity in myelodysplastic syndromes, acute myeloid leukemia, acute promyelocytic leukemia, and breast tumors (MacKinnon et al., 2011; Paolicchi et al., 2013; Xu et al., 2018; Wang X. et al., 2019). This evidence concerns the gene KDM3B and neoplasm.